The goals of the core are to provide all projects with centralized leadership and administrative support, and to ensure effective communication among all projects and cores so that translational objectives are being met. To achieve this goal the core will arrange internal group meetings including the monthly investigator meeting, executive committee meetings and invited research lectures. It will oversee the overall fiscal and budgetary management of the SPORE and provide assistance to each project and core leader, with a particular focus on assisting budgetary planning for clinical translation. The Core will also use its discretionary funds to support new research opportunities or unexpected costs. During the initial funding period, this core has monitored each project with input from the Executive Committee and Advisory Board, and modified projects and incorporated new directions as necessary. For the current proposal. Administrative Core leaders will ensure continued SPORE oversight by convening meetings of the Internal and Advisory Boards and assessing and implementing their recommendations. The activities of the Career Development and the Developmental Research Programs will both be co-ordinated with other SPORE activities through this Administrative Core to ensure that the objectives of these programs are being met. Finally the Administrative Core will communicate with the NCI SPORE program Staff and encourage and facilitate collaboration with other SPORES and networks.

Public Health Relevance

The Administrative Core supports the leadership of all SPORE projects and cores and integrates these with the Career Development and Developmental Research Programs. It organizes meetings to monitor progress and promote collaboration and identifies new research opportunities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA126752-06
Application #
8339662
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
6
Fiscal Year
2012
Total Cost
$149,624
Indirect Cost
$72,324
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Morita, Daisuke; Nishio, Nobuhiro; Saito, Shoji et al. (2018) Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Mol Ther Methods Clin Dev 8:131-140
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139
Lyon, Deborah; Lapteva, Natasha; Gee, Adrian P (2018) Absence of Replication-Competent Retrovirus in Vectors, T Cell Products, and Patient Follow-Up Samples. Mol Ther 26:6-7
Su, Jianzhong; Huang, Yung-Hsin; Cui, Xiaodong et al. (2018) Homeobox oncogene activation by pan-cancer DNA hypermethylation. Genome Biol 19:108
Nabekura, Tsukasa; Chen, Zhiying; Schroeder, Casey et al. (2018) Crk Adaptor Proteins Regulate NK Cell Expansion and Differentiation during Mouse Cytomegalovirus Infection. J Immunol 200:3420-3428
Shum, Thomas; Kruse, Robert L; Rooney, Cliona M (2018) Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opin Biol Ther 18:653-664
Bajgain, Pradip; Tawinwung, Supannikar; D'Elia, Lindsey et al. (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 6:34
McLaughlin, Lauren P; Rouce, Rayne; Gottschalk, Stephen et al. (2018) EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood 132:2351-2361
McClain, Kenneth L; Picarsic, Jennifer; Chakraborty, Rikhia et al. (2018) CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer 124:2607-2620
Gomes-Silva, Diogo; Ramos, Carlos A (2018) Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line. Biotechnol J 13:

Showing the most recent 10 out of 270 publications